A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Pancreatic neuroendocrine tumors (PanNET) are rare and aggressive, necessitating a deeper understanding of their molecular drivers.
• The PI3K-Akt-mTOR pathway is implicated in PanNET progression, with mTOR inhibitors showing therapeutic potential.
• PHLDA3 is a newly identified tumor suppressor that negatively regulates Akt activation by interfering with PIP3 binding.

Purpose of the Study:

• To investigate the role of the PHLDA3 gene in the development and progression of PanNET.
• To explore PHLDA3 alterations as a potential common mechanism in various neuroendocrine tumors (NET).

Main Methods:

• Analysis of loss-of-heterozygosity and DNA methylation at the PHLDA3 locus in PanNET samples.
• Assessment of PHLDA3 gene transcription levels in relation to observed genetic alterations.
• Comparison of PHLDA3 alterations in PanNET with those found in lung neuroendocrine tumors (NET).

Main Results:

• Frequent loss-of-heterozygosity and DNA methylation were observed at the PHLDA3 locus in PanNET.
• These genetic alterations led to significant suppression of PHLDA3 transcription.
• Similar PHLDA3 gene alterations were detected in lung NET, suggesting a shared mechanism.

Conclusions:

• Functional loss of the PHLDA3 gene, due to genetic alterations and transcriptional suppression, is a key event in PanNET development.
• The findings suggest that PHLDA3 inactivation may be a common pathway contributing to the pathogenesis of various neuroendocrine tumors.
• Targeting pathways affected by PHLDA3 loss could offer new therapeutic strategies for NET patients.